JP2011516027A - レプリキンピーク遺伝子が関与する病原体および悪性腫瘍の致死性を判定する方法 - Google Patents

レプリキンピーク遺伝子が関与する病原体および悪性腫瘍の致死性を判定する方法 Download PDF

Info

Publication number
JP2011516027A
JP2011516027A JP2009546425A JP2009546425A JP2011516027A JP 2011516027 A JP2011516027 A JP 2011516027A JP 2009546425 A JP2009546425 A JP 2009546425A JP 2009546425 A JP2009546425 A JP 2009546425A JP 2011516027 A JP2011516027 A JP 2011516027A
Authority
JP
Japan
Prior art keywords
replikin
virus
seq
peak gene
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009546425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516027A5 (https=
Inventor
ボゴーク，サミュエル
エス． ボゴーク，エレノア
ウィンストン ボゴーク，サミュエル
ボルサンニ，アン−エレノア，ボゴーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/755,597 external-priority patent/US20080260764A1/en
Priority claimed from US11/923,559 external-priority patent/US8050871B2/en
Application filed by Individual filed Critical Individual
Publication of JP2011516027A publication Critical patent/JP2011516027A/ja
Publication of JP2011516027A5 publication Critical patent/JP2011516027A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2009546425A 2007-01-18 2008-01-18 レプリキンピーク遺伝子が関与する病原体および悪性腫瘍の致死性を判定する方法 Pending JP2011516027A (ja)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US88096607P 2007-01-18 2007-01-18
US60/880,966 2007-01-18
US89809707P 2007-01-30 2007-01-30
US60/898,097 2007-01-30
US11/755,597 2007-05-30
US11/755,597 US20080260764A1 (en) 2006-05-30 2007-05-30 Replikin peptides and uses thereof
US95474307P 2007-08-08 2007-08-08
US60/954,743 2007-08-08
US93549907P 2007-08-16 2007-08-16
US60/935,499 2007-08-16
US93581607P 2007-08-31 2007-08-31
US60/935,816 2007-08-31
US98233307P 2007-10-24 2007-10-24
US98233607P 2007-10-24 2007-10-24
US98233807P 2007-10-24 2007-10-24
US60/982,338 2007-10-24
US11/923,559 2007-10-24
US11/923,559 US8050871B2 (en) 2006-10-24 2007-10-24 Method of predicting influenza outbreaks by correlating an increase in replikin count in shrimp white spot syndrome virus and/or taura syndrome virus
US60/982,333 2007-10-24
US60/982,336 2007-10-24
US99167607P 2007-11-30 2007-11-30
US60/991,676 2007-11-30
PCT/US2008/000645 WO2008143717A2 (en) 2007-01-18 2008-01-18 Methods of determining lethality of pathogens and malignancies involving replikin peak genes

Publications (2)

Publication Number Publication Date
JP2011516027A true JP2011516027A (ja) 2011-05-26
JP2011516027A5 JP2011516027A5 (https=) 2011-07-07

Family

ID=40032325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009546425A Pending JP2011516027A (ja) 2007-01-18 2008-01-18 レプリキンピーク遺伝子が関与する病原体および悪性腫瘍の致死性を判定する方法

Country Status (6)

Country Link
US (1) US20090017052A1 (https=)
EP (1) EP2126140A4 (https=)
JP (1) JP2011516027A (https=)
AU (2) AU2008253721A1 (https=)
CA (1) CA2676028A1 (https=)
WO (1) WO2008143717A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
EP2471552B1 (en) 2005-03-08 2015-05-06 MedImmune, LLC Reassortant influenza viruses
US8050871B2 (en) * 2006-10-24 2011-11-01 Samuel Bogoch Method of predicting influenza outbreaks by correlating an increase in replikin count in shrimp white spot syndrome virus and/or taura syndrome virus
JP5675348B2 (ja) 2007-05-30 2015-02-25 ボゴーク，サミュエル 水産養殖における無脊椎動物の病原性感染に対する合成レプリキンペプチド
US20090269367A1 (en) * 2008-04-23 2009-10-29 Samuel Bogoch Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles
RU2523587C2 (ru) * 2008-07-11 2014-07-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейрамидазы вируса гриппа
SG193783A1 (en) * 2008-08-08 2013-10-30 Samuel Bogoch Methods of predicting cancer lethality using replikin counts
US20100144589A1 (en) * 2008-08-08 2010-06-10 Samuel Bogoch Methods of predicting cancer lethality using replikin counts
US9233148B2 (en) 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
CN107375919B (zh) 2009-03-27 2022-07-29 台湾地区“中央研究院” 抗病毒免疫的方法和组合物
CN103977394B (zh) * 2009-07-17 2016-03-09 翰林大学校产学协力团 包含脂质体包胶的寡核苷酸和表位的免疫刺激性组合物
US9594599B1 (en) * 2009-10-14 2017-03-14 Nvidia Corporation Method and system for distributing work batches to processing units based on a number of enabled streaming multiprocessors
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
WO2013013075A2 (en) 2011-07-20 2013-01-24 Samuel Bogoch Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
JP2013049645A (ja) * 2011-08-30 2013-03-14 National Agriculture & Food Research Organization 口蹄疫ウイルスと反応する抗体、当該抗体を用いて口蹄疫ウイルスを検出する方法、および当該抗体を含んでいるストリップ
US20130243803A1 (en) 2012-03-09 2013-09-19 Samuel Bogoch Therapies, vaccines, and predictive methods for infectious salmon anemia virus
WO2014074927A1 (en) * 2012-11-09 2014-05-15 Samuel Bogoch Methods of identifying, preventing, and treating virulent aleutian mink disease virus using replikin sequences
WO2014165274A2 (en) * 2013-03-13 2014-10-09 Samuel Bogoch Methods of diagnosing, preventing, and treating drug-resistant pathogenic infections using replikin sequences
WO2014172664A2 (en) * 2013-04-19 2014-10-23 Samuel Bogoch Replikin-based compounds for prevention and treatment of h7 strains of influenza

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3018A (en) * 1843-03-21 Coupling for qttilting-frames
US3019A (en) * 1843-03-30 Hatching chickens
US6002A (en) * 1849-01-02 Screw-wrench for grasping cylindrical forms
WO2006088962A2 (en) * 2005-02-16 2006-08-24 Samuel Bogoch Replikin peptides and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0221748A3 (en) * 1985-11-01 1988-10-12 Samuel Dr. Bogoch A process for the production of human antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5104854A (en) * 1989-02-01 1992-04-14 Washington University Antiviral peptides
US5280113A (en) * 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5231167A (en) * 1989-09-08 1993-07-27 The Regents Of The University Of California Immunoglobulin-binding polypeptides
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
US20050271676A1 (en) * 1993-03-05 2005-12-08 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
US6242578B1 (en) * 1994-02-17 2001-06-05 Samuel Bogoch Aglyco products and methods of use
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US6023659A (en) * 1996-10-10 2000-02-08 Incyte Pharmaceuticals, Inc. Database system employing protein function hierarchies for viewing biomolecular sequence data
WO1998023755A1 (en) * 1996-11-26 1998-06-04 Bio Merieux Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
US6070126A (en) * 1997-06-13 2000-05-30 William J. Kokolus Immunobiologically-active linear peptides and method of identification
JPH11232291A (ja) * 1998-02-16 1999-08-27 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質立体構造データベース検索方法
US7176275B2 (en) 1998-09-04 2007-02-13 Samuel Bogoch Anthrax and small pox replikins and methods of use
US6175830B1 (en) * 1999-05-20 2001-01-16 Evresearch, Ltd. Information management, retrieval and display system and associated method
US6470277B1 (en) * 1999-07-30 2002-10-22 Agy Therapeutics, Inc. Techniques for facilitating identification of candidate genes
US7774144B2 (en) * 2001-10-26 2010-08-10 Samuel Bogoch System and method for identifying complex patterns of amino acids
US7189800B2 (en) * 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7442761B2 (en) * 2003-06-06 2008-10-28 Samuel Bogoch Replikin peptides and uses thereof
US7420028B2 (en) * 2001-03-27 2008-09-02 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
US7452963B2 (en) * 2001-03-27 2008-11-18 Samuel Bogoch Replikin peptides and antibodies therefore
US7894999B2 (en) * 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
WO2004085455A1 (en) * 2003-03-24 2004-10-07 The University Of Hong Kong A diagnostic assay for the human virus causing severe acute respiratory syndrome (sars)
WO2005012337A2 (en) * 2003-07-15 2005-02-10 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
KR20090016671A (ko) * 2006-05-30 2009-02-17 사무엘 보고치 레플리킨 펩티드 및 이의 용도
WO2008073161A2 (en) * 2006-08-14 2008-06-19 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
US8050871B2 (en) * 2006-10-24 2011-11-01 Samuel Bogoch Method of predicting influenza outbreaks by correlating an increase in replikin count in shrimp white spot syndrome virus and/or taura syndrome virus
JP5675348B2 (ja) * 2007-05-30 2015-02-25 ボゴーク，サミュエル 水産養殖における無脊椎動物の病原性感染に対する合成レプリキンペプチド

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3018A (en) * 1843-03-21 Coupling for qttilting-frames
US3019A (en) * 1843-03-30 Hatching chickens
US6002A (en) * 1849-01-02 Screw-wrench for grasping cylindrical forms
WO2006088962A2 (en) * 2005-02-16 2006-08-24 Samuel Bogoch Replikin peptides and uses thereof

Also Published As

Publication number Publication date
AU2008253721A1 (en) 2008-11-27
EP2126140A2 (en) 2009-12-02
CA2676028A1 (en) 2008-11-27
WO2008143717A3 (en) 2009-03-26
WO2008143717A8 (en) 2009-07-30
EP2126140A4 (en) 2012-03-28
WO2008143717A2 (en) 2008-11-27
AU2014203304A1 (en) 2014-07-10
US20090017052A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
JP2011516027A (ja) レプリキンピーク遺伝子が関与する病原体および悪性腫瘍の致死性を判定する方法
US8050871B2 (en) Method of predicting influenza outbreaks by correlating an increase in replikin count in shrimp white spot syndrome virus and/or taura syndrome virus
Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus Update on avian influenza A (H5N1) virus infection in humans
Cattoli et al. Emergence of a new genetic lineage of Newcastle disease virus in West and Central Africa—implications for diagnosis and control
Tsai et al. Antigenic and genotypical characterization of Newcastle disease viruses isolated in Taiwan between 1969 and 1996
EP1526175B2 (en) Coronavirus, nucleic acid, protein and methods for the generation of vaccine, medicaments and diagnostics
JP5675348B2 (ja) 水産養殖における無脊椎動物の病原性感染に対する合成レプリキンペプチド
Hou et al. A highly pathogenic GI-19 lineage infectious bronchitis virus originated from multiple recombination events with broad tissue tropism
EP2027146B1 (en) Replikin peptides and uses thereof
US20090269367A1 (en) Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles
Bourogâa et al. S1 gene sequence analysis of new variant isolates of avian infectious bronchitis virus in Tunisia
Baratelli et al. Genetic characterization of influenza A viruses circulating in pigs and isolated in north-east Spain during the period 2006–2007
Mossie et al. A compressive review on Newcastle disease virus in Ethiopia
Yang et al. Isolation and identification of Eurasian avian-like H1N1 swine influenza virus and evaluation of their pathogenicity and immune protective effects in pigs
Murphy et al. Molecular characterization of epizootic hemorrhagic disease virus serotype 1 associated with a 1999 epizootic in white-tailed deer in the eastern United States
WO2009132209A2 (en) Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles
Shrestha et al. Avian/Bird flu: A review: H5N1 outbreaks in Nepal
KR20090094838A (ko) 레플리킨 피크 유전자와 관련된 병원체 및 악성 종양의 치사율 측정 방법
CN101688236A (zh) 确定包含Replikin Peak基因的病原体和恶性肿瘤的致死性的方法
Opriºan et al. Molecular analysis of the first avian influenza H5N1 isolates from fowl in Romania
Marchenko et al. Characterization of the H5N1 influenza virus isolated during an outbreak among wild birds in Russia (Tuva Republic) in 2010
RU2825670C1 (ru) Реассортантный штамм вируса гриппа А/17/Дарвин/2018/154 (H1N1)pdm09 для производства живой гриппозной интраназальной вакцины для взрослых и для детей
Conly et al. Ode to oseltamivir and amantadine?
Eid et al. The highly pathogenic avian influenza H5N8 sublineage 2.3. 4.4 b virus: A critical analysis of genetic steadiness based on full HA gene sequencing in Egypt
Al-Talabani et al. Serological and Molecular detection of highly pathogenic avian influenza of Layan Hens circulating in Diyala Governorate

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130411

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150714